SBI Pharma Fund (Equity, Equity Sectoral-pharma)

High
19 yrs 3 monthsStarted on:14 Jul 1999
₹ 1108.09 Cras on: 19 Sep 2018
Long Term Horizon
2.60%
Capital Appreciation

Minimum Investment

  • ₹ 5000.00 for Lumpsum

Investment Objective

The scheme seeks to provide the investors with the opportunity of long-term capital appreciation by investing in a diversified portfolio of equity and equity related securities in Healthcare space.

Exit Load

Scheme Documents

Similar Funds
RELIANCE PHARMA FUND
Current NAV 1114.25
Return (CAGR) 21.57%
Crisil Ranking NA
Value Research NA
uti healthcare
Current NAV 1114.25
Return (CAGR) 13.93%
Crisil Ranking NA
Value Research NA

Tenure

TenureReturns (CAGR)
1 Month6.54
3 Month12.68
1 YR5.82

SIP Returns

TenureReturns (CAGR)
1 YR15.16
2 YR3.58
5 YR4.85
10 YR16.29

Portfolio

Company Name% Assets
Sun Pharmaceutical Inds. Ltd.10.6
Aurobindo Pharma Ltd.9.65
Strides Pharma Science Ltd.8.96
Divi's Laboratories Ltd.6.6
Cipla Ltd.5.38
Cadila Healthcare Ltd.5.09
Alkem Laboratories Ltd.4.58
Biocon Ltd.4.51
Dr. Reddy's Laboratories Ltd.4.5
Torrent Pharmaceuticals Ltd.4.42

Top Sectoral Holdings

Sector Name% Assets
Healthcare98.16

Indicators

LabelValue
Portfolio turnover ratio49
Standard Deviation16.86%
Beta0.73%

Tanmaya Desai

Mr. Desai is a B.E. (Electronics), MBA (Finance) and CFA (Level III).
Prior to joining SBI Mutual Fund he has worked with D.J. Sanghvi College of Engineering and Patni Computer Systems Ltd.
© CRISIL Limited 2017. All Rights Reserved